CA2866707A1 - Inhibiteurs selectifs d'histone desacetylase 6 - Google Patents
Inhibiteurs selectifs d'histone desacetylase 6 Download PDFInfo
- Publication number
- CA2866707A1 CA2866707A1 CA2866707A CA2866707A CA2866707A1 CA 2866707 A1 CA2866707 A1 CA 2866707A1 CA 2866707 A CA2866707 A CA 2866707A CA 2866707 A CA2866707 A CA 2866707A CA 2866707 A1 CA2866707 A1 CA 2866707A1
- Authority
- CA
- Canada
- Prior art keywords
- alkyl
- compound
- aryl
- previous
- heteroaryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
- C07C275/20—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
- C07C275/24—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C275/30—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by halogen atoms, or by nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C275/32—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms
- C07C275/34—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms having nitrogen atoms of urea groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/72—Two oxygen atoms, e.g. hydantoin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/72—Two oxygen atoms, e.g. hydantoin
- C07D233/76—Two oxygen atoms, e.g. hydantoin with substituted hydrocarbon radicals attached to the third ring carbon atom
- C07D233/78—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/26—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/14—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (15)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261607803P | 2012-03-07 | 2012-03-07 | |
US61/607,803 | 2012-03-07 | ||
US201261618150P | 2012-03-30 | 2012-03-30 | |
US61/618,150 | 2012-03-30 | ||
US201261648946P | 2012-05-18 | 2012-05-18 | |
US61/648,946 | 2012-05-18 | ||
US201261651896P | 2012-05-25 | 2012-05-25 | |
US201261651595P | 2012-05-25 | 2012-05-25 | |
US61/651,896 | 2012-05-25 | ||
US61/651,595 | 2012-05-25 | ||
US201261674942P | 2012-07-24 | 2012-07-24 | |
US61/674,942 | 2012-07-24 | ||
US201261715379P | 2012-10-18 | 2012-10-18 | |
US61/715,379 | 2012-10-18 | ||
PCT/US2013/029521 WO2013134467A1 (fr) | 2012-03-07 | 2013-03-07 | Inhibiteurs sélectifs d'histone désacétylase 6 |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2866707A1 true CA2866707A1 (fr) | 2013-09-12 |
Family
ID=49117326
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2866707A Abandoned CA2866707A1 (fr) | 2012-03-07 | 2013-03-07 | Inhibiteurs selectifs d'histone desacetylase 6 |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP2822926A4 (fr) |
JP (1) | JP6233812B2 (fr) |
AU (1) | AU2013230881A1 (fr) |
CA (1) | CA2866707A1 (fr) |
WO (1) | WO2013134467A1 (fr) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ724030A (en) | 2014-03-12 | 2017-09-29 | Chong Kun Dang Pharmaceutical Corp | Novel compounds as histone deacetylase 6 inhibitors and pharmaceutical compositions comprising the same |
WO2015154065A1 (fr) * | 2014-04-05 | 2015-10-08 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Inhibition d'histone désacétylase 6 pour améliorer la fonction de lymphocytes t pendant une réponse anti-tumorale et une vaccination par peptides tumoraux |
EP3169326B1 (fr) * | 2014-07-15 | 2021-03-31 | The Johns Hopkins University | Suppression de cellules suppressives d'origine myéloïde et blocage de point de contrôle immunitaire |
KR102538658B1 (ko) | 2014-08-04 | 2023-05-31 | 누에볼루션 에이/에스 | 염증성, 대사성, 종양성 및 자가면역성 질환의 치료에 유용한 피리미딘의 임의적 융합 헤테로시클릴-치환 유도체 |
US20190194654A1 (en) * | 2014-10-24 | 2019-06-27 | Astrazeneca Ab | Combination |
WO2016110541A1 (fr) | 2015-01-08 | 2016-07-14 | Universiteit Gent | Inhibiteurs sélectifs de hdac6 et leurs utilisations |
WO2016126726A1 (fr) | 2015-02-02 | 2016-08-11 | Forma Therapeutics, Inc. | Acides hydroxamiques bicycliques [4,6,0] en tant qu'inhibiteurs hdac6 |
CN107873023B (zh) | 2015-02-02 | 2021-07-23 | 福马治疗股份有限公司 | 作为hdac抑制剂的3-烷基-4-酰氨基-双环[4,5,0]异羟肟酸 |
FI3328843T3 (fi) | 2015-07-27 | 2023-01-31 | 1,3,4-oksadiatsolisulfonamidijohdannaisyhdisteitä histonideasetylaasi-6:n inhibiittoreina ja samaa käsittävä farmaseuttinen koostumus | |
BR112017027798B1 (pt) | 2015-07-27 | 2023-12-19 | Chong Kun Dang Pharmaceutical Corp | Compostos de derivado de 1,3,4-oxadiazol sulfamida como inibidor de histona desacetilase 6 e a composição farmacêutica que compreende os mesmos |
PL3330259T3 (pl) | 2015-07-27 | 2021-02-08 | Chong Kun Dang Pharmaceutical Corp. | Związek pochodna amidowa 1,3,4-oksadiazolu jako inhibitor deacetylazy histonowej 6 i kompozycja farmaceutyczna go zawierająca |
HRP20220003T1 (hr) | 2015-08-04 | 2022-04-01 | Chong Kun Dang Pharmaceutical Corp. | Spojevi derivata 1,3,4-oksadiazola kao inhibitori histonske deacetilaze 6, i farmaceutski pripravak koji ih sadrži |
US10555935B2 (en) | 2016-06-17 | 2020-02-11 | Forma Therapeutics, Inc. | 2-spiro-5- and 6-hydroxamic acid indanes as HDAC inhibitors |
CN110291089B (zh) | 2017-01-17 | 2022-05-27 | 海帕瑞吉尼克斯股份有限公司 | 用于促进肝再生或者减少或预防肝细胞死亡的蛋白激酶抑制剂 |
CN110730660A (zh) * | 2017-04-26 | 2020-01-24 | 伊利诺伊大学评议会 | Nrf和HIF活化剂/HDAC抑制剂和使用其的治疗方法 |
WO2019054865A1 (fr) * | 2017-09-14 | 2019-03-21 | ACADEMISCH ZIEKENHUIS LEIDEN (h.o.d.n. LUMC) | Immunothérapie reposant sur des lymphocytes t |
NL2019548B1 (en) * | 2017-09-14 | 2019-03-27 | Academisch Ziekenhuis Leiden | T-cell based immunotherapy |
CN108191748A (zh) * | 2018-01-24 | 2018-06-22 | 齐鲁师范学院 | 一种含芳杂环氨基肟类化合物、制备方法及其用途 |
KR102316234B1 (ko) | 2018-07-26 | 2021-10-22 | 주식회사 종근당 | 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 유도체 화합물 및 이를 포함하는 약제학적 조성물 |
MX2021014372A (es) | 2019-05-31 | 2022-01-06 | Chong Kun Dang Pharmaceutical Corp | Compuestos derivados de 1,3,4-oxadiazol como inhibidores de histona desacetilasa 6, y la composicion farmaceutica que comprende los mismos. |
US20230079386A1 (en) | 2019-05-31 | 2023-03-16 | Chong Kun Dang Pharmaceutical Corp. | 1,3,4-oxadiazole homophthalimide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same |
KR102331206B1 (ko) * | 2019-12-09 | 2021-11-25 | 계명대학교 산학협력단 | 히스톤 탈아세틸효소 억제 활성을 갖는 신규 화합물 및 이의 의학적 용도 |
EP4076657A1 (fr) | 2019-12-20 | 2022-10-26 | Nuevolution A/S | Composés actifs vis-à-vis des récepteurs nucléaires |
KR102537616B1 (ko) | 2020-02-25 | 2023-05-26 | 주식회사 종근당 | 히스톤 탈아세틸화 효소 6 억제제로서의 1,3,4-옥사다이아졸 유도체 화합물 및 이를 포함하는 약제학적 조성물 |
KR102537615B1 (ko) | 2020-02-25 | 2023-05-30 | 주식회사 종근당 | 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 유도체 화합물 및 이를 포함하는 약제학적 조성물 |
MX2022012259A (es) | 2020-03-31 | 2022-12-08 | Nuevolution As | Compuestos activos frente a receptores nucleares. |
EP4126874A1 (fr) | 2020-03-31 | 2023-02-08 | Nuevolution A/S | Composés actifs vis-à-vis des récepteurs nucléaires |
KR102576148B1 (ko) | 2020-04-13 | 2023-09-07 | 주식회사 종근당 | 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 유도체 화합물 및 이를 포함하는 약제학적 조성물 |
WO2022013728A1 (fr) | 2020-07-14 | 2022-01-20 | Chong Kun Dang Pharmaceutical Corp. | Nouveaux composés utilisés en tant qu'inhibiteurs de l'histone désacétylase 6 et composition pharmaceutique les comprenant |
KR20220030134A (ko) | 2020-09-02 | 2022-03-10 | 주식회사 종근당 | 히스톤 탈아세틸화효소 6 억제제로서의 새로운 구조의 화합물 및 이를 포함하는 약제학적 조성물 |
KR20220139752A (ko) | 2021-04-08 | 2022-10-17 | 주식회사 종근당 | 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 싸이오카보닐 화합물 및 이를 포함하는 약제학적 조성물 |
KR20230144686A (ko) | 2022-04-07 | 2023-10-17 | 주식회사 종근당 | 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 유도체 화합물 및 이의 용도 |
KR20240035172A (ko) | 2022-09-08 | 2024-03-15 | 주식회사 종근당 | 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 유도체 화합물 및 이의 용도 |
WO2024079682A1 (fr) | 2022-10-14 | 2024-04-18 | Chong Kun Dang Pharmaceutical Corp. | Composés de sulfoximine utilisés en tant qu'inhibiteur de l'histone désacétylase 6, et composition pharmaceutique les comprenant |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1133317A1 (fr) | 1998-11-26 | 2001-09-19 | Pentapharm AG | Conjugues systeme de transport |
US20030070691A1 (en) * | 2000-08-03 | 2003-04-17 | Anthony Giletto | Biocide formation via ozonation |
EP1345956A2 (fr) | 2000-10-13 | 2003-09-24 | University of Lausanne | Liberation intracellulaire d'effecteurs biologiques par de nouvelles sequences de peptides transporteurs |
US7033597B2 (en) | 2000-10-13 | 2006-04-25 | Université de Lausanne | Intracellular delivery of biological effectors |
AU2003211362A1 (en) * | 2002-02-21 | 2003-09-09 | Osaka Industrial Promotion Organization | N-hydroxycarboxamide derivative |
CA2543570A1 (fr) * | 2003-10-27 | 2005-05-06 | S*Bio Pte Ltd | Hydroxamates connectes a l'acyluree et a la sulfonyluree |
JP2008505971A (ja) * | 2004-07-12 | 2008-02-28 | メルク エンド カムパニー インコーポレーテッド | ヒストン脱アセチル化酵素阻害剤 |
WO2006013209A2 (fr) * | 2004-08-02 | 2006-02-09 | Genmedica Therapeutics Sl | Composes inhibant les amine oxydases contenant du cuivre, et utilisations correspondantes |
US20070066646A1 (en) * | 2005-08-02 | 2007-03-22 | Genmedica Therapeutics Sl | Compounds for Inhibiting Copper-Containing Amine Oxidases and Uses Thereof |
US20110212969A1 (en) * | 2010-02-26 | 2011-09-01 | Millennium Pharmaceuticals, Inc. | Substituted hydroxamic acids and uses thereof |
US20150197497A1 (en) | 2011-06-24 | 2015-07-16 | Dana-Farber Cancer Institute, Inc. | Selective inhibitors of histone deacetylase isoform 6 and methods thereof |
-
2013
- 2013-03-07 WO PCT/US2013/029521 patent/WO2013134467A1/fr active Application Filing
- 2013-03-07 EP EP13758416.5A patent/EP2822926A4/fr not_active Withdrawn
- 2013-03-07 AU AU2013230881A patent/AU2013230881A1/en not_active Abandoned
- 2013-03-07 CA CA2866707A patent/CA2866707A1/fr not_active Abandoned
- 2013-03-07 JP JP2014561101A patent/JP6233812B2/ja not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
WO2013134467A1 (fr) | 2013-09-12 |
JP6233812B2 (ja) | 2017-11-22 |
EP2822926A4 (fr) | 2015-11-04 |
AU2013230881A1 (en) | 2014-10-30 |
EP2822926A1 (fr) | 2015-01-14 |
JP2015510886A (ja) | 2015-04-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2866707A1 (fr) | Inhibiteurs selectifs d'histone desacetylase 6 | |
US10227295B2 (en) | Selective histone deactylase 6 inhibitors | |
US9956192B2 (en) | Selective histone deactylase 6 inhibitors | |
JP5934184B2 (ja) | ヒストンデメチラーゼlsd1及び/又はlsd2の阻害剤としてのトラニルシプロミン誘導体 | |
JP5699152B2 (ja) | リジン特異的デメチラーゼ−1阻害剤およびその使用 | |
RU2581367C2 (ru) | Соединения для лечения рака | |
US20230348389A1 (en) | Piperidine derivatives as hdac1/2 inhibitors | |
JP5868948B2 (ja) | リジン特異的脱メチル化酵素1阻害薬およびその使用 | |
US10508122B2 (en) | Heterocyclic hydroxamic acids as protein deacetylase inhibitors and dual protein deacetylase-protein kinase inhibitors and methods of use thereof | |
US20100292229A1 (en) | Tryphostin-analogs for the treatment of cell proliferative diseases | |
JP2016536354A (ja) | 非ホジキンリンパ腫を治療するための、hdac阻害剤単独またはbtk阻害剤との組み合わせ | |
ES2718637T3 (es) | Compuestos para el tratamiento del cáncer | |
KR102157912B1 (ko) | 효소-활성화 화합물 및 조성물 | |
JP2019147818A (ja) | 癌の処置のための化合物 | |
US10870618B2 (en) | Histone deacetylase inhibitors and uses thereof | |
US11591301B2 (en) | Indoleamine-2,3-dioxygenase inhibitor, preparation method therefor and use thereof | |
KR101624344B1 (ko) | 히스톤 탈아세틸화 효소 억제 활성을 갖는 신규한 3-치환-2-옥소인돌린 기반 n-히드록시프로펜아미드 및 이를 유효성분으로 포함하는 항암용 조성물 | |
CA2962597A1 (fr) | Forme medicamenteuse solide du chlorhydrate de n-(2,6-bis(1-methylethyl)phenyl)-n'-((1-(4-(dimethylamino) phenyl)cyclopentyl)methyl)uree et compositions, procedes et kits s'y rapportant | |
KR101900574B1 (ko) | 신규한 n-히드록시벤즈아미드 및 이의 용도 | |
KR20220033689A (ko) | 히스톤 탈아세틸화효소 억제 활성을 갖는 신규 화합물 및 이의 용도 | |
EP3712127A1 (fr) | Nouveaux inhibiteurs de l'histone déacétylase 10 | |
WO2023150569A1 (fr) | Composés d'imidazotétrazine et traitement de cancers résistants au tmz | |
US20200039944A1 (en) | Cathepsin-d and angiogenesis inhibitors and compositions thereof for treating breast cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Dead |
Effective date: 20180307 |